ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

NEO vs MRK // NET PROFIT MARGIN

NeoGenomics Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: NEO 1 — MRK 9
▲ NET PROFIT MARGIN LEADER: MRK
net-margins
-14.80%
net-margins
28.10%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NEO VS. MRK) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC NEO MRK SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 43.20% 74.80% -31.60 MRK /gross-margins <GO>
Return on Invested Capital (ROIC) -9.00% 20.70% -29.70 MRK /roic <GO>
EV/EBITDA & P/E Valuation — 15.3x — TIE /valuation <GO>
Free Cash Flow Yield -0.94% 3.42% -4.36 MRK /fcf-yield <GO>
Operating Margin -15.90% 34.30% -50.20 MRK /operating-margins <GO>
Net Profit Margin ACTIVE -14.80% 28.10% -42.90 MRK /net-margins <GO>
Revenue Growth (YoY) — 1.30% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 2.26% -2.26 MRK /dividend-safety <GO>
Altman Z-Score & Debt/Equity 2.72 5.19 -2.47 MRK /balance-sheet <GO>
Piotroski F-Score Quality 5/9 7/9 -2.00 MRK /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 55.3 51.7 +3.60 NEO /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 0.92 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 18.4x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $2.32B $361.02B -$358.70B MRK /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR NEO REV MRK REV NEO GROSS % MRK GROSS % NEO FCF MRK FCF
FY 2025 $727.3M $65.01B 43.2% 74.8% -$21.8M $12.36B
FY 2024 $660.6M $64.17B 43.9% 76.3% -$34.0M $18.10B
FY 2023 $0 $60.12B — — -$2.0M $10.30B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NEO // BETA —
MRK // BETA 0.92